A simple eye test could change the way that Alzheimer’s disease is detected and managed. A multi-site clinical trial conducted by Cognoptix showed that its Sapphire II eye test, which is designed to identify Alzheimer’s disease patients via a beta-amyloid (Ab) signature in their eyes, resulted in high rates of success. To find out more, watch this video on VisionMonday.com.